Información de la revista
Vol. 36. Núm. 3.mayo - junio 2016
Páginas e1-e52 Páginas 217-332
Descargar PDF
Más opciones de artículo
Vol. 36. Núm. 3.mayo - junio 2016
Páginas e1-e52 Páginas 217-332
Original article
Open Access
Kidney injury after sodium phosphate solution beyond the acute renal failure
Daño renal después de preparación colónica con soluciones de fosfato. Más allá del fracaso renal agudo
Gema Fernández-Juáreza,
Autor para correspondencia

Corresponding author at: Department of Nephrology, Hospital Fundación Alcorcón, Alcorcón, Madrid, Spain. Tel.: +34 607288402.
, Leticia Parejoa, Javier Villacortaa, Ana Tatoa, Ramiro Cazara, Carmen Guerrerob, Isabel Martinez Marina, Javier Ocañaa, Angel Mendez-Abreua, Katia Lópeza, Enrique Grussa, Eduardo Gallegoa
a Department of Nephrology, Hospital Universitario Fundación de Alcorcón, Alcorcón, Spain
b Department of Pathology, Hospital Universitario Fundación de Alcorcón, Alcorcón, Spain
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Descargar PDF
Figuras (1)
Tablas (2)
Table 1. Baseline clinical characteristics of 12 patients with phosphate nephropathy.
Table 2. Renal outcome in 12 patients with phosphate nephropathy.
Mostrar másMostrar menos
Background and objectives

Screening colonoscopy with polipectomy reduces colonorectal cancer incidence and mortality. An adequate bowel cleansing is one of the keys to achieving best results with this technique. Oral sodium phosphate solution (OSP) had a widespread use in the 90s decade. Its efficacy was similar to polyethylene glycol (PEG) solution, but with less cost and convenient administration. Series of patients with acute renal failure due to OSP use have been reported. However, large cohorts of patients found no difference in the incidence of renal damage between these two solutions.


From 2006 to 2009 we identified twelve cases of phosphate nephropathy after colonoscopy prepared with OSP. All patients were followed up to six months. All patients had received just a single dose.


We analyzed 12 cases with phosphate nephropathy; three patients debuted with AKI and nine patients had chronic renal injury. Four cases were confirmed with renal biopsy. One patient with AKI needed hemodialysis at diagnosis without subsequent recovery. Two patients (both with chronic damage) fully recovered their previous renal function. The remaining patients (nine) had an average loss of estimated glomerular filtration rate of 24ml/min/1.73m2.


The use of OSP can lead to both acute and chronic renal damage. However, chronic injury was the most common pattern. Both forms of presentation imply a significant and irreversible loss of renal function. Further studies analyzing renal damage secondary to bowel cleaning should consider these two different patterns of injury.

Chronic renal failure
Renal failure
ACE inhibitor
Antecedentes y objetivos

La colonoscopia con polipectomía con fines de cribado reduce la incidencia del cáncer colorrectal y la mortalidad por esta enfermedad. Una preparación colónica aceptable es una de las claves para conseguir mejores resultados con esta técnica. Las soluciones de fosfato de sodio oral (OSP) fueron muy utilizadas en la década de los noventa del siglo pasado. Su eficacia era similar a la de las soluciones de polietilenglicol (PEG), pero más baratas y con una administración sencilla. Se han descrito series de casos de pacientes con insuficiencia renal aguda provocada por OSP. Sin embargo, en cohortes amplias de pacientes no se observó ninguna diferencia en la incidencia de daño renal entre estas dos soluciones.


Entre 2006 y 2009 identificamos 12 casos de nefropatía por fosfato tras preparación con OSP para colonoscopia. Se realizó el seguimiento de todos los pacientes durante 6 meses. Todos los pacientes habían recibido una única dosis.


Analizamos 12 casos de nefropatía por fosfato; 3 se manifestaron con IRA y 9 presentaron daño renal crónico. Cuatro de los casos se confirmaron mediante biopsia renal. Un paciente con IRA precisó hemodiálisis en el momento del diagnóstico, sin que experimentara recuperación posterior. Dos pacientes (ambos con daño crónico) recuperaron totalmente su función renal anterior. Los demás pacientes (9) presentaron una pérdida media en la filtración glomerular estimada de 24ml/min/1,73m2.


El uso de OSP puede ocasionar daño renal tanto agudo como crónico. Sin embargo, el daño crónico fue el más frecuente. Ambas formas de presentación suponen una pérdida considerable e irreversible de función renal. Nuevos estudios que analicen el daño renal secundario a preparación colónica deben considerar estos dos patrones distintos de daño.

Palabras clave:
Insuficiencia renal crónica
Insuficiencia renal
Texto completo

The use of colonoscopy for routine screening for colon and rectal cancer has been one of the most successful public health projects worldwide. Although colonoscopy is the most frequent technique that requires a proper bowel preparation, it could be necessary in others diagnosis tests: CT colonography, barium enema and surgery on the gastrointestinal tract. Effective preparation requires an adequate level of cleansing.

The osmotically balanced, polyethylene glycol-based electrolyte solutions are elected because they are safer and faster than large volume saline-based electrolyte solutions. Many patients have great difficulty to drink the large volume, that can result in unsuccessful preparation and poorly cleansed colon, and therefore, inadequate study assessment.1 The small volume of oral sodium phosphate solution (OSP) was associated with improved patients compliance, less discomfort, and superior colonic cleansing.

The OSPS is not exempt from risks. It can cause transient hyperphosphatemia and can induce intravascular volume contraction. There have been reports of serious adverse events, including death, and there have been case reports of nephrocalcinosis with renal failure associated with the use of oral sodium phosphate.2–4 In fact, in 2008 FDA issued a warning about the use of OSP in patients with chronic kidney disease (CKD) or major cardiovascular comorbidities.

Unfortunately, the results of the available epidemiologic data from large populations are quite confusing some studies reporting a potent association5–7 and others reporting non-significant trends toward better kidney outcomes after OSP compared with other purgatives.2,8 A major limitation of most of theses studies is they just consider renal damage when an acute renal failure happens. However the chronic damage has been well documented with the use of this purgative solution.9,10

Given the large number of patients exposed to OSP annually, clarification of this association is compelling. We present a series of patients with acute and chronic renal damage link to use of OSP.

Material and methodsPatient selection and study design

From 2006 to 2009 we identified 12 patients with suspected nephropathy after colonoscopy prepared by phosphosoda. The clinical suspicion of PN (was based on the presence of an acute o chronic renal function deterioration (>50% from basal serum creatinine) chronologically related to colonoscopy. In all the patients, the presence of proteinuria o hematuria was ruled out by repeated urine analysis, also presence of urinary tract obstruction or other urinary tract abnormalities was excluded by appropriate radiological examinations. Patients with clinical or analytical data that suggested systemic diseases were excluded.

All included patients had at least one Scr determination in the three months before the colonoscopy and it was considered as baseline Scr. The highest Scr value registered was recorded, as well as the need for acute dialysis. The creatinine concentration at 6 months after the procedure was recorded.

Medical records of the patients were reviewed for this study. We reviewed for age, gender, medical history (high blood pressure, smoker, hypercholesterolemia and diabetes mellitus) and medication (ACE inhibitors, diuretics). Estimated glomerular filtration rate (eGFR) was calculated according to the MDRD4 formula. All cases happened in a single hospital. The Scr was measured in a single laboratory and by the kinetic Jaffé blank correction method.

Final Scr was defined as the value obtained 6 months after withdrawal of the offending drug. An incomplete recovery of baseline renal function was defined by an Scr value higher than at least 25% of the baseline value.

The recommended regimen of OSP solution (Casen Fleet Laboratories) consisted of two 45ml doses taken 10–12h apart, the evening before and the morning of colonoscopy. Each 45ml dose contained 21.6g of monobasic sodium phosphate (NaH2PO4) and 8.1g of dibasic sodium phosphate (Na2H-PO4), which is equivalent to 5.8g of elemental phosphorus. The 5.8g of phosphorus was diluted into a single eight ounce glass and administered twice in a 12–24h period (total dose 11.6g of phosphorus).

Statistical analysis

The baseline characteristics are expressed as means±standard deviation (SD). The groups were compared using the 2-sample t test, χ2-test and Fischer exact tests, respectively. The 2-sample t test was used to compare the creatinine level and eGFR between the study and control groups. The χ2-test was used to compare group characteristics of diabetes, hypertension, and use of angiotensin receptor blockers (ARBs), angiotensin-converting enzyme inhibitors and diuretics. P<0.05 was considered significant. Statistics were calculated using SPSS for Windows, version 11 (SPSS Inc., Chicago, IL, USA).


Twelve cases of phosphate nephropathy were diagnosed: four of them were confirmed by renal biopsy. The baseline characteristics of patients in both groups are shown in Table 1.

Table 1.

Baseline clinical characteristics of 12 patients with phosphate nephropathy.

  Age (years)  Gender  eGFR (ml/min/1.73m2)©  Hypertension  Diabetes mellitus  ACEi-ARB  Diuretics  Renal biopsy  Course 
Case 1  61  Man  63.6  No  No  No  No  Yes  Acute 
Case 2  85  Female  41.3  Yes  Yes  No  Yes  –  Chronic 
Case 3  71  Man  70.7  Yes  Yes  Yes  Yes  Yes  Acute 
Case 4  73  Female  73.2  Yes  Yes  Yes  Yes  –  Chronic 
Case 5  84  Man  59.6  Yes  No  Yes  Yes  –  Chronic 
Case 6  59  Female  137.9  Yes  No  Yes  Yes  –  Chronic 
Case 7  70  Female  95.6  Yes  Yes  Yes  Yes  Yes  Chronic 
Case 8  72  Man  54.5  Yes  No  Yes  Yes  –  Chronic 
Case 9  72  Man  54.5  Yes  No  Yes  Yes  –  Acute 
Case 10  73  Female  65.6  Yes  No  Yes  No  Yes  Chronic 
Case 11  75  Man  54.0  Yes  No  Yes  No  –  Chronic 
Case 12  92  Man  35.2  Yes  No  Yes  No  –  Chronic 

© Modification of the diet in renal disease (MDRD)-4 equation was used to estimate glomerular filtration rate (eGFR).

ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers.

There were a predominance of cases of men, 68.2% with mean age 69.44±7.2 years. The main co-morbidities in our patients were high blood pressure 91.6% and DM 33.3%. The 73.3% of the patients received treatment with ACE inhibitors or ARBs, and the 66.5% received treatment with diuretics.

All patients received just one dose of OSP. None of them were subjected to repeated cleanings intestinal in a short period. One patient undergone endoscopy procedures during hospitalization for acute indications (case 1). The other eleven patients received the OSPS preparation and performed the colonoscopy in outpatient regimen.

Kidney function

Before the procedure, eGFR was >60ml/min/1.73m2 in 7 patients. CKD stage 3a was present in 3 patients and CKD 3b in 2 patients. None has CKD 4 or 5 stage.

Three patients debuted as acute renal failure (two cases confirmed with renal biopsy) and nine patients developed chronic renal damage (two cases confirmed with renal biopsy). No significant differences were found in the baseline renal function, age, sex, treatment with ACEi or ARBs, diuretics, mellitus diabetes or hypertension.

In the group of patients who debuted as AKI (acute kidney injury), one of patients begun with nausea and vomiting hours after colonoscopy (case 1). The others two patients debuted in the week after the OSP administration. In the patients with delayed debut the average time until the diagnosis was 54 days (15–120 days). All of them were asymptomatic or pauci symptomatic and the renal damage was an accidental diagnosis.

Patients presented with AKI had a higher initial loss of glomerular filtration rate, but no significantly, than the patients with chronic presentation (52±9.9ml/min/1.73m2 vs 38±24ml/min/1.72m2, NS).

Calcium and phosphorus levels were normal in the delayed analysis. None other alterations were finding.

Renal follow up

One patient of the acute course group needed substitutive renal therapy in the moment of diagnosis, without later recovery. Six months later, none of the remainder two patients of this group recovered completely the glomerular filtration rate, although they got it partially. The final average loss was 22.5±9.7ml/min/1.73m2.

In the group with delayed presentation, six months later of colonoscopy just two patients recovered renal function as previous baseline and nine patient did not improved. In the patients who did not recovered baseline renal function, the final average loss of glomerular filtration rate was 26±20ml/min/1.73m2 (Table 2).

Table 2.

Renal outcome in 12 patients with phosphate nephropathy.

  Course  Baseline eGFR (ml/min/1.73m2Peak eGFR (ml/min/1.73m2eGFR 6 month after (ml/min/1.73m2ΔeGFR 6m after (ml/min/1.73m2
Case 1  Acute  63.6  7.9  41.6  22.0 
Case 2  Chronic  41.3  30.2  48.2  −6.9 
Case 3  Acute  70.7  9.9  HD  HD 
Case 4  Chronic  73.2  36.9  50.5  22.7 
Case 5  Chronic  59.6  28.6  38.3  21.3 
Case 6  Chronic  137.9  51.9  76.5  61.4 
Case 7  Chronic  95.6  29.7  39.2  56.3 
Case 8  Chronic  54.5  15.3  19.6  34.9 
Case 9  Acute  54.5  12.8  31.5  23.0 
Case 10  Chronic  65.6  8.6  27.3  38.3 
Case 11  Chronic  54.0  20.7  31.0  23.1 
Case 12  Chronic  35.2  18.0  23.3  11.9 

HD: hemodialysis.

Renal biopsy findings

In four patients a biopsy was performed. The renal biopsy findings in PN primary involve the tubules and were dependent on the time interval between the preparation with oral sodium phosphate and renal biopsy. The biopsy from patients with AKI acute degenerative changes predominated a resemble findings seen an acute tubular necrosis.11 The renal biopsies performed in patients with chronic course showed tubular atrophy and interstitial fibrosis. Regardless of the degree of acuity of chronicity, the hallmark of PN was abundant tubular and less prominent interstitial calcium phosphate deposits (Fig. 1). The calcifications do not polarize and have a strong histochemical reaction with the von Kossa stain, indicating that they are composed of calcium phosphate.

Fig. 1.

Renal biopsy findings in chronic phosphate nephropathy. (a) Case of chronic phosphate nephropathy with abundant intraluminal and intracellular calcifications in distal tubules accompanied by tubular atrophy and fibrosis (hematoxylin and eosin) and (b) a positive histochemical reaction with the von Kossa stain confirms that the tubular concretions are composed of calcium phosphate.


Ten years ago some cases of PN began to be published.4 The former cases were presented as an acute illness that manifested as tetany, acute kidney disease or cardiovascular collapse usually within hours of bowel preparation. Patients had marked hyperphosphatemia and hypocalcemia and some patients required even hemodialysis.12

Although case reports and case series provide strong support for an etiological relationship between OSP and the development of PN, epidemiological studies have showed less consistent results. In an retrospective observational study of 9799 patients who filled a prescription for an OSP or PEG (polyethylene glycol), 114 patients (1.16%) developed AKI: 1.29% of the 6432 patients who received OSPS and 0.92% of the 3367 patients who received PEG. The PEG group included patients who were significantly older and had a higher incidence of diabetes mellitus, hypertension, CHF, CKD, diuretics use and ACEi or ARBs use (p<0.05). In the multiple logistic regression models adjusted for covariates and suspected risk factors, OSP was found to be the strongest risk factor for the development or AKI after colonoscopy (OR 2.35, CI 95% 1.51–3.66) when compared with PEG. When a more “strict” definition of AKI was considered (doubling of serum creatinine vs >50% serum creatinine increase), the OSP purgative use remained significantly associated with increased risk for AKI (OR 3.52, CI 95% 1.13–10.93).5

In a recent, large retrospective cohort study using a US-based administrative claims database. The number of the patients included was impressive: 121,226 received OSP pill preparation and 429,430 received PEG. Patients were followed up to 6 months for AKI, renal failure and dialysis. The investigators did not find any increase risk of AKI in OSP pill users compared with PEG (0.2% vs 0.3%). The investigators acknowledged that the study of administrative claims for AKI outcomes may be an insensitive measure of renal dysfunction.8

Brunelli et al. undertook a systematic review and metaanalysis that concluded that it is not possible to discern if an association between OSP exposure and AKI exits. The use of different AKI definitions and significant heterogeneity among the studies referred to choice of bowel preparation, patients populations, baseline renal function, limited the result of the study.13

The chronic form of kidney damage due to OSP agents may present weeks after the initial exposure and may be identified as the result of an investigation of mild or non-specific symptoms such as fatigue. Sometimes, it is just discovered by a casual analysis and the anamnesis is the clue. This was the most frequent pattern in our study. The 65% of the patients were referred for study by nephrologist for increasing in serum creatinine in casual analysis.

This form of presentation requires the inclusion of this entity in the differential diagnosis of CKD. The nephrologist or physician who treats these patients should consider the possibility of PN in patients with renal damage without proteinuria or hematuria when the patient has undergone a digestive test prepared OSD.

Whereas until now to estimate the incidence of kidney disease for OSP we consider just the case presented as AKI, ignoring cases of delaying presentation. It may mean that this problem is more prevalent than is currently recognized. In fact, in the studies that analyze the safe of bowel preparation for colonoscopy the follow up was too short to identify it.

But, the true issue of this complication is not to know the AKI incidence if the secondary chronic loss of renal function over time. The outcomes of these patients are very inconstant: in most of cases of our study represent a substantial and irreversible loss of glomerular filtration. In Hurst et al.,5 just the 16% of patients returned to baseline renal function. They could not know if any of these patients requires renal replacement. In cases reported at least four patients developed ESRD.14 In most of studies this information is not available. In our study one patient (case 3) required renal replacement at diagnosis time and she did not recover renal function. The other patients had an average chronic loss glomerular filtration>20ml/min/1.72m2.

Different options to get an adequate level of cleansing, such as PEG, can also cause renal damage.5,15 The AKI incidence reported for PEG vary between 0.92% and 6%. If we consider that the damage is mainly due to renal hypoperfusion by dehydration, we could think that this injury would less severe and more reversible, although to our knowledge, none study has analyzed the long lasting effect of this injury.

The presence of CKD before the colonoscopy has been considered as the most weighty risk factor to develop kidney damage.6,14,16 However in our study the 63% of the patients had an eGFR>60ml/min/1.73m2. In fact, a lot of cases with normal o nearly normal baseline renal function with kidney injury induced OSP have been published.17 Some studies have suggested that females, above all elderly females, are at greater risk than males for developing PN.14 They might have reduced renal capacity of handle a phosphate load and their smaller body mass makes then more sensitive to fluid loss. This loss of volumen in conjunction with limited oral intake dictated by precolonoscopy protocols, may exacerbate some of the electrolyte abnormalities and the risk of renal failure among patients receiving these agents. Drugs that impact intravascular volumen and renal perfusion may increase the risk of kidney injury after OSP use, including diuretics, ACE inhibitors, angiotensin receptor blockers and non-steroidal anti-inflammatory agents.

The standard dose of OSP contains 11.6g of phosphorus. About 57% of the dose is excreted in feces, 15% in urine and 28% is retained in the body for 24h.18 The total amount of phosphate increases after the first and second doses to fourfold and eightfold of the baseline level respectably and remains elevates at 24h. These results suggest that the second dose of OSP is particularly dangerous because renal reabsorption of phosphate is fully inhibited at the time of dosing and thus the urinary concentrations of phosphate remains elevated for prolonged period.

In summary, the administration of oral sodium phosphate can cause an intense renal injury, sometimes depend of dialysis and often irreversible. This side effect does not always occur in high-risk patients and the most common pattern of presentation was renal chronic disease. The series that study this adverse effect should consider both the acute and chronic pattern damage.

Authors contribution

G. Fernandez-Juárez and L. Parejo designed the study. They have drafted and made the critical revision of the manuscript. A. Tato, J. Villacorta, J. Ocaña, R. Cazar, I. Martinez, A. Mendez, J. Ocaña, K. Lopez, E. Gruss, E. Gallego have collected the data and made the critical reviewed of the manuscript. C. Guerrero performed the renal biopsies studies and reviewed the manuscript.


The study has not received any support, grants. None of the authors have received any consulting fees or honoraria related to the study.

Conflict of interests

The authors declare no conflict of interest.


The authors would like to thank Internal Medicine Department, Hospital Móstoles, Madrid. This study has been supported by RedinRen.

S.J. Vanner, P.H. MacDonald, W.G. Paterson, R.S. Prentice, L.R. Da Costa, I.T. Beck.
A randomized prospective trial comparing oral sodium phosphate with standard polyethylene glycol-based lavage solution (Golytely) in the preparation of patients for colonoscopy.
Am J Gastroenterol, 85 (1990), pp. 422-427
R. Abaskharoun, W. Depew, S. Vanner.
Changes in renal function following administration of oral sodium phosphate or polyethylene glycol for colon cleansing before colonoscopy.
Can J Gastroenterol, 21 (2007), pp. 227-231
G.S. Markowitz, M.A. Perazella.
Acute phosphate nephropathy.
Kidney Int, 76 (2009), pp. 1027-1034
S. Desmeules, M.J. Bergeron, P. Isenring.
Acute phosphate nephropathy and renal failure.
N Engl J Med, 4 (2003), pp. 1006-1007
F.P. Hurst, E.M. Bohen, E.M. Osgard, D.K. Oliver, N.P. Das, S.W. Gao, et al.
Association of oral sodium phosphate purgative use with acute kidney injury.
J Am Soc Nephrol, 18 (2007), pp. 3192-3198
A. Khurana, L. McLean, S. Atkinson, C.J. Foulks.
The effect of oral sodium phosphate drug products on renal function in adults undergoing bowel endoscopy.
Arch Intern Med, 24 (2008), pp. 593-597
M.A. Korsten, A.M. Spungen, A.R. Rosman, H.R. Ancha, J.B. Post, S. Shaw, et al.
A prospective assessment of renal impairment after preparation for colonoscopy: oral sodium phosphate appears to be safe in well-hydrated subjects with normal renal status.
Dig Dis Sci, 55 (2010), pp. 2021-2029
J.B. Layton, P.J. Klemmer, C.F. Christiansen, A.S. Bomback, J.A. Baron, R.S. Sandler, et al.
Sodium phosphate does not increase risk for acute kidney injury after routine colonoscopy, compared with polyethylene glycol.
Clin Gastroenterol Hepatol, 29 (2014), pp. 1514-1521
J. Weiss, M.L. Thorp.
Acute phosphate nephropathy: a cause of chronic kidney disease.
BMJ Case Rep, 2011 (2011),
G.S. Markowitz, J. Whelan, V.D. D’Agati.
Renal failure following bowel cleansing with a sodium phosphate purgative.
Nephrol Dial Transplant, 20 (2005), pp. 850-851
G.S. Markowitz, S.H. Nasr, P. Klein, H. Anderson, J.I. Stack, L. Alterman, et al.
Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing.
Hum Pathol, 35 (2004), pp. 675-684
N. Ullah, R. Yeh, M. Ehrinpreis.
Fatal hyperphosphatemia from a phosphosoda bowel preparation.
J Clin Gastroenterol, 34 (2002), pp. 457-458
S.M. Brunelli.
Association between oral sodium phosphate bowel preparations and kidney injury: a systematic review and meta-analysis.
Am J Kidney Dis, 53 (2009), pp. 448-456
G.S. Markowitz, M.B. Stokes, J. Radhakrishnan, V.D. D’Agati.
Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure.
J Am Soc Nephrol, 16 (2005), pp. 3389-3396
A.K. Singal, A.S. Rosman, J.B. Post, W.A. Bauman, A.M. Spungen, M.A. Korsten.
The renal safety of bowel preparations for colonoscopy: a comparative study of oral sodium phosphate solution and polyethylene glycol.
Aliment Pharmacol Ther, 1 (2008), pp. 41-47
Y. Gumurdulu, E. Serin, B. Ozer, A. Gokcel, S. Boyacioglu.
Age as a predictor of hyperphosphatemia after oral phosphosoda administration for colon preparation.
J Gastroenterol Hepatol, 19 (2004), pp. 68-72
M. Ahmed, P. Raval, G. Buganza.
Oral sodium phosphate catharsis and acute renal failure.
Am J Gastroenterol, 91 (1996), pp. 1261-1262
V. Patel, M. Emmett, C.A. Santa Ana, J.S. Fordtran.
Pathogenesis of nephrocalcinosis after sodium phosphate catharsis to prepare for colonoscopy: intestinal phosphate absorption and its effect on urine mineral and electrolyte excretion.
Hum Pathol, 38 (2007), pp. 193-194
Copyright © 2016. Sociedad Española de Nefrología
Opciones de artículo
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?